GlassScriptPhysician profile
Arpita Patel
NPI 1780084111
$1,516.59
in general payments reported to CMS, 2019-2025
20 companies · $83.72 in 2025
The $83.72 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $442 · 2023: $409 · 2024: $297 · 2025: $83.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $277.42 | 2021-2024 | Symplicity G3 |
| Abbott Laboratories | $240.60 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $193.62 | 2021-2023 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.99 | 2021-2023 | Jardiance |
| Scpharmaceuticals INC. | $139.45 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $106.51 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $96.06 | 2023-2025 | Gemtesa |
| Amgen INC. | $61.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.04 | 2023 | Gvoke Hypopen |
| Novo Nordisk INC | $31.49 | 2022 | |
| Abbvie INC. | $28.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.02 | 2023 | Cycloset |
| Insulet Corporation | $18.25 | 2023 | Omnipod |
| Boston Scientific Corporation | $17.56 | 2024 | Wavewriter Alpha Prime 16 |
| Becton, Dickinson and Company | $16.16 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $15.30 | 2025 | Isturisa |
| Cequr Corporation | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.98 | 2021 | |
| Ibsa Pharma INC. | $13.33 | 2023 | Tirosint, Licart |
| Astrazeneca Pharmaceuticals LP | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpita Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.